Finance

Lists
STAR:NSE
Strides Pharma Science Ltd
1 009,00 ₹
-0,51%
(-5,20) 1D
5 նոյ, 15:30:00 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for STAR...
Open
1 025,00 ₹
High
1 028,10 ₹
Low
993,60 ₹
Mkt. cap
93,01 մլրդ
Avg. vol.
342,37 հզր
Volume
438,89 հզր
Dividend
0,50%
Quarterly dividend
1,25 ₹
Ex-dividend date
31 հլս, 2026 թ.
P/E ratio
15,08
52-wk high
1 260,90 ₹
52-wk low
768,65 ₹
EPS
66,90 ₹
Shares outstanding
89,55 մլն
No. of employees
4 հզր
Open
1 025,00 ₹
High
1 028,10 ₹
Low
993,60 ₹
Mkt. cap
93,01 մլրդ
Avg. vol.
342,37 հզր
Volume
438,89 հզր
Dividend
0,50%
Quarterly dividend
1,25 ₹
Ex-dividend date
31 հլս, 2026 թ.
P/E ratio
15,08
52-wk high
1 260,90 ₹
52-wk low
768,65 ₹
EPS
66,90 ₹
Shares outstanding
89,55 մլն
No. of employees
4 հզր
News stories
From web sources and news partners
Profile
Strides Pharma Science Limited is an Indian pharmaceutical company, headquartered at Bangalore. The company manufactures pharmaceutical products, over-the-counter drugs and nutraceuticals. Products include softgel capsules, hard-gel capsules, tablets and dry and wet injectables. The company has 15 manufacturing sites in six countries and marketing presence in 50 countries. The company partners with generic companies to supply retail and hospital generics in injectable products and softgels. The company's stock trades on the Bombay Stock Exchange and on the National Stock Exchange of India. Strides Arcolab changed name to Strides Shasun Ltd after an amalgamation of Shasun Pharmaceuticals with Strides Arcolab. In September 2014, the Board of Directors of both the companies had approved a scheme of amalgamation between the two companies. Arun Kumar is the founder and chairman, and has been on the board as managing director since its inception. Wikipedia
About Strides Pharma Science Ltd
CEO-
Employees3,54 հզր
Founded1990
HeadquartersԲանգալոր, Կառնատակա, Հնդկաստան
SectorHealth Care
Industry-
Last report
30 հոկ, 2026 թ.
Fiscal period
Q2 2027
- / -
Revenue / Est. (INR)
14,30 մլրդ / 14,15 մլրդ
Fiscal Q2 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
2026 թ. սեպ
Revenue
11,95 մլրդ
13,23 մլրդ
12,65 մլրդ
14,30 մլրդ
Cost of goods sold
4,63 մլրդ
7,19 մլրդ
4,95 մլրդ
6,29 մլրդ
Cost of revenue
4,63 մլրդ
7,19 մլրդ
4,95 մլրդ
6,29 մլրդ
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,30 մլրդ
3,45 մլրդ
2,43 մլրդ
2,38 մլրդ
Operating expense
5,46 մլրդ
4,91 մլրդ
5,97 մլրդ
6,07 մլրդ
Total operating expenses
10,09 մլրդ
12,10 մլրդ
10,92 մլրդ
12,36 մլրդ
Operating income
1,85 մլրդ
1,13 մլրդ
1,73 մլրդ
1,94 մլրդ
Other non operating income
1,07 մլրդ
-1,66 մլրդ
48,90 մլն
40,83 մլն
EBT including unusual items
2,45 մլրդ
1,48 մլրդ
2,00 մլրդ
1,50 մլրդ
EBT excluding unusual items
2,49 մլրդ
502,07 մլն
1,36 մլրդ
1,52 մլրդ
Income tax expense
373,53 մլն
187,70 մլն
341,23 մլն
163,18 մլն
Effective tax rate
15,22%
12,68%
17,09%
10,85%
Other operating expenses
2,66 մլրդ
928,53 մլն
2,97 մլրդ
3,11 մլրդ
Net income
2,02 մլրդ
1,27 մլրդ
1,57 մլրդ
1,31 մլրդ
Net profit margin
16,92%
9,59%
12,40%
9,15%
Earnings per share
-
-
-
-
Interest and investment income
-
404,82 մլն
-
-
Interest expense
-433,79 մլն
-130,82 մլն
-405,61 մլն
-465,41 մլն
Net interest expenses
-433,79 մլն
274,00 մլն
-405,61 մլն
-465,41 մլն
Depreciation and amortization charges
506,23 մլն
532,49 մլն
563,99 մլն
572,15 մլն
EBITDA
2,25 մլրդ
1,55 մլրդ
2,15 մլրդ
2,51 մլրդ
Gain or loss from assets sale
-
-
-
-
Upcoming events
AI content may include mistakes. Learn more
Google Apps